Recent News

• 09.09.2025 - Capricor Therapeutics Responds to FDA Posting of Complete Response Letter (CRL) for Deramiocel
• 09.09.2025 - Capricor Therapeutics Responds to FDA Posting of Complete Response Letter (CRL) for Deramiocel
• 08.18.2025 - Capricor Therapeutics Announces First Subjects Dosed in Phase 1 Clinical Trial of Novel Exosome-Based Vaccine
• 08.18.2025 - Capricor Therapeutics Announces First Subjects Dosed in Phase 1 Clinical Trial of Novel Exosome-Based Vaccine
• 08.11.2025 - Capricor Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
• 08.11.2025 - Capricor Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
• 08.08.2025 - Capricor Therapeutics Announces Type A Meeting Scheduled with U.S. FDA
• 08.08.2025 - Capricor Therapeutics Announces Type A Meeting Scheduled with U.S. FDA
• 08.06.2025 - Capricor Therapeutics to Present Second Quarter 2025 Financial Results and Recent Corporate Update on August 13
• 08.06.2025 - Capricor Therapeutics to Present Second Quarter 2025 Financial Results and Recent Corporate Update on August 13

Recent Filings

• 08.11.2025 - EX-99.1 EX-99.1
• 08.11.2025 - 8-K Current report
• 08.11.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 07.29.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 07.11.2025 - 8-K Current report
• 07.11.2025 - EX-99.1 EX-99.1